about
Anti-RANKL therapy for bone tumours: Basic, pre-clinical and clinical evidencesChemotherapy- and irradiation-induced bone loss in adults with solid tumorsA phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant diseaseAtypical femoral fracture after receiving antiresorptive drugs in breast cancer patients with bone metastasis.Src inhibitors in the treatment of metastatic bone disease: rationale and clinical dataSurvival benefit of zoledronic Acid in postmenopausal breast cancer patients receiving aromatase inhibitorsDifferences in vitamin D status may account for unexplained disparities in cancer survival rates between African and white AmericansCorrelation of baseline biomarkers with clinical outcomes and response to fulvestrant with vandetanib or placebo in patients with bone predominant metastatic breast cancer: An OCOG ZAMBONEY sub-studyPositive predictive values of the coding for bisphosphonate therapy among cancer patients in the Danish National Patient Registry.Histomorphometric and microarchitectural analyses using the 2 mm bone marrow trephine in metastatic breast cancer patients-preliminary resultsRegulation of VEGF by mevalonate pathway inhibition in breast cancerDecreasing frequency of osteonecrosis of the jaw in cancer and myeloma patients treated with bisphosphonates: the experience of the oncology network of piedmont and aosta valley (north-Western Italy)Pathways to breast cancer recurrence.Nanotechnology in the targeted drug delivery for bone diseases and bone regeneration.Evaluation of socket healing in patients undergoing bisphosphonate therapy: experience of a single Institution.Denosumab and giant cell tumour of bone-a review and future management considerations.Bisphosphonates and their Role in Therapy for Breast Cancer - Results from the PATH Biobank.Targeted drug delivery of near IR fluorescent doxorubicin-conjugated poly(ethylene glycol) bisphosphonate nanoparticles for diagnosis and therapy of primary and metastatic bone cancer in a mouse model.A phase 2 trial exploring the clinical and correlative effects of combining doxycycline with bone-targeted therapy in patients with metastatic breast cancer.Intra-tumor delivery of zoledronate mitigates metastasis-induced osteolysis superior to systemic administration.Treatment of bisphosphonate-related osteonecrosis of the jaws - a report of seven cases.Macrophages in cancer and infectious diseases: the 'good' and the 'bad'.Denosumab in patients with cancer-a surgical strike against the osteoclast.Epidemiology, clinical manifestations, risk reduction and treatment strategies of jaw osteonecrosis in cancer patients exposed to antiresorptive agents.The inhibition of human farnesyl pyrophosphate synthase by nitrogen-containing bisphosphonates. Elucidating the role of active site threonine 201 and tyrosine 204 residues using enzyme mutants.Emerging drugs for the treatment of bone metastasis.Tumor-Stroma Crosstalk in Bone Tissue: The Osteoclastogenic Potential of a Breast Cancer Cell Line in a Co-Culture System and the Role of EGFR Inhibition.The Role of the Microenvironment in Prostate Cancer-Associated Bone Disease.An open-label, prospective, observational study of the efficacy of bisphosphonate therapy for painful osteoid osteoma.Relevance of Bisphosphonate Therapy in Osteoporosis and Cancer--No Cause for Alarm in Dentistry.Are serotonin metabolite levels related to bone mineral density in patients with neuroendocrine tumours?Integrin αvβ3 Signaling in Tumor-Induced Bone Disease.Repurposing Drugs in Oncology (ReDO)-nitroglycerin as an anti-cancer agent.Profile of bacteria colonizing the exposed bone of patients with anti-osteoclastic drug-related osteonecrosis of the jaws.Bisphosphonate-related osteonecrosis of the jaw: awareness and level of knowledge of Lebanese physicians.Pure anti-tumor effect of zoledronic acid in naïve bone-only metastatic and locally advanced breast cancer: proof from the "biological window therapy".Bisphosphonates, healthcare professionals and oral health.Synthesis and pharmacological evaluation of 99mTc-labeled imidazolyl-containing diphosphonic acid as a novel bone imaging agent.Comparative risks for cancer associated with use of calcitonin, bisphosphonates or selective estrogen receptor modulators among osteoporosis patients: a population-based cohort study.External validity of the Tokuhashi score in patients with vertebral metastasis.
P2860
Q26863493-E5CF7E47-8AA8-4960-998E-4275407C2885Q28084019-66272671-6350-453C-9BC9-309B34F60733Q33628466-6B10BDB1-524F-44CA-9D5B-A4CC95B0D35AQ33844438-6A2B2DCB-2652-482A-9BF0-4A651FD3AB06Q34182834-F4032FF9-59CC-457E-A54F-3E47799EEF66Q34779663-6D44BB86-77E3-4022-9C31-C6791DA8E53DQ36187658-752C1D46-7C06-4533-AA57-44375EAFBF05Q36207673-31B788BA-CD4C-4356-A02B-C1D698DBF961Q36221541-46492C8C-D8E9-4D99-914E-CED3AF58048BQ36491435-57506CE3-015B-4C3D-85E7-81CAF5280D3CQ36491540-D12F046F-AA3A-401D-9472-D1BD3FAB091AQ36691952-2CA51D39-52F1-4AF7-BC20-6C164D4F0BDCQ36702139-EC6DE1C2-0DCA-4428-BE89-ADB2B4BF57DFQ36975264-25640BFD-7C60-4E0D-8256-FCF65F47C39CQ37063582-E98E0DF9-620C-416D-95C0-7C5C60F4272AQ37248014-9C123D06-E785-4A54-A32B-148DA53D1FC4Q37395467-05F1FA0D-A500-45BD-B661-4F76597BD082Q37476433-A295B949-0BFA-40A0-AA09-92C1F1D13B05Q37499970-D83E91FB-ECD6-4AE5-9181-69CA913D2422Q37603941-E4A9A03D-4BF4-4C88-A4B4-683ADC5A594AQ37657684-148AD38F-BA65-4430-A2E1-EA7C7C256C12Q37945300-F3ACC9B6-A9F3-4449-AE7F-CA4A0D4A08BCQ37974570-CC330212-C645-4B15-9C8F-6C6299642632Q38184580-CE9D0702-834E-42FC-B343-049CE2753CE2Q38296795-C05CC64C-FA7E-4BA6-8FB7-C287ADDCF73FQ38538263-AC653439-96A2-4501-89E5-FF80848D7376Q38696082-C4BF8138-4D8E-4E1D-9C07-0657101AC5DDQ38938475-C4DFC8F6-ED30-4CB4-B86E-F05519183CC5Q39150039-58EAEA9E-B8BA-43D8-A2C8-3A4DD004B07FQ39169596-2FF73FAD-0988-4E55-BB04-017A23737202Q39398828-63224E82-DC4F-4CA0-89DC-9F098BE1CF25Q39429448-57ED4B5D-85D4-4B66-B06B-E1CC70734B0CQ40468319-4DFBC512-7308-4D6C-8F6A-BD4A413817B2Q40612308-194958B9-EE34-4DB1-AB98-8EF61CF21DA0Q41449657-4A5599EA-ADE8-4535-B353-BD7C00E655D6Q42453200-322DDF51-9840-414E-B64C-58E5FFC4E219Q45209793-ECB2B263-B61C-42DB-85CC-B02E070FBF97Q46205142-3345DC59-A6B1-4758-9BDE-9F7F680D0C74Q47598003-5C5C43D1-680A-4825-9E5E-483C9EA85F9AQ47866383-B3935516-E138-451C-A4AF-23C9B745AE30
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Bisphosphonates in oncology.
@ast
Bisphosphonates in oncology.
@en
Bisphosphonates in oncology.
@nl
type
label
Bisphosphonates in oncology.
@ast
Bisphosphonates in oncology.
@en
Bisphosphonates in oncology.
@nl
prefLabel
Bisphosphonates in oncology.
@ast
Bisphosphonates in oncology.
@en
Bisphosphonates in oncology.
@nl
P1433
P1476
Bisphosphonates in oncology.
@en
P2093
Eugene V McCloskey
Robert E Coleman
P356
10.1016/J.BONE.2011.02.003
P577
2011-02-21T00:00:00Z